Hite Christopher 4

What Happened

• Christopher Hite, a director of Vera Therapeutics (VERA), received a derivative equity award on 2026-03-05 covering 24,937 shares. The reported acquisition price is $0.00 (total value $0 on grant), indicating an equity award/option grant rather than an open-market purchase.

Key Details

• Transaction date: 2026-03-05; Filing date: 2026-03-09 (File appears timely).
• Type/code: A (Grant/Award/Other acquisition); reported price: $0.00; reported value: $0.
• Vesting: Per the filing footnote, the shares subject to the option vest monthly over a three-year period, contingent on continuous service.
• Shares owned after transaction: Not specified in the summary information provided in your prompt.

Context

• This is a derivative award (an option or similar equity grant) that vests over time; it does not represent an immediate market purchase or sale. Such awards are common for directors and are intended as compensation or retention incentives. The filing does not indicate any immediate sale of shares.